Patient Involvement working group is determined to address the third and fifth goal of the Task Force, as stated in the Declaration of Intent:

‘Goal 3: Cancer medicines that have a distinctive therapeutic added value should reach patients in a timely manner, in the safest way and at affordable prices. The patients should be fully informed of the possible benefits and harms.’

 ‘Goal 5: Patients should at all times be involved in the decision-making process (e.g. joint decision making concerning policies as well as treatment process).’

 Members of WG3 are looking for solutions on (i) how to best improve the communication between patients and healthcare professionals in order to improve the knowledge of patients about their disease and options of treatment; and (ii) how to involve patients in the discussion on access to medicines at the national and international level.